Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· July 23, 2026
Novocure Reports Second Quarter 2026 Financial Results
View original at finance.yahoo.comNovocure Reports Second Quarter 2026 Financial Results Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU M…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
This was Novocure's strongest quarter to date, with record net revenues and active patients on therapy; the company continues to launch its therapies in multiple markets and is making material progress on its path to profitability.
60% confidence
Cited in these Via News reports
- Cancer's two big bets: a personalised vaccine that held melanoma at bay, and AI that designs the drugs. Here is what is verified and what is not →
- Oncology's Next Wave Arrives on a Calendar: A Cancer Vaccine Readout on Oct. 24, an FDA Decision on Nov. 14 →
- Oncology's Q4 Decision Window: Three Dated Catalysts, One Already Delivered, and a Sector Splitting Between Cash-Rich and Cash-Careful →
- Oncology's Three Bets: New Drug Types, AI-Built Medicines and a $5.8 Billion Care Deal, and the Cash Behind One Closely Watched Drug →